Call for proposals focused on proteostasis, senescence, and other novel approaches

CLEVELAND and NEW YORK, April 1, 2024 /PRNewswire/ -- Harrington Discovery Institute Center for Brain Health Medicines at University Hospitals and the Alzheimer's Drug Discovery Foundation (ADDF) announce a joint request for proposals for the 2024 ADDF-Harrington Scholar Award. The ADDF-Harrington Scholar Award is designed to accelerate the translation of innovative research that could treat, prevent, slow, or reverse Alzheimer's disease or related dementias.

The Request for Proposals (RFP) is open to academic investigators at accredited medical centers, research institutions, and universities in the United States, Canada, and the United Kingdom. Researchers working on drug development programs that are relevant to, but not presently focused on, the Alzheimer's field are strongly encouraged to apply.

This award provides a combination of financial support and expert drug development guidance. Award recipients will receive financial support up to $600,000 over two years, dedicated drug development and project management support, and an opportunity to qualify for investment funds.

The 2024 ADDF-Harrington Scholar RFP places high priority on targets related to emerging therapeutic areas for dementia, particularly:

Proteostasis (including autophagy, lysosomal biogenesis, proteasomal degradation, post-translational modification associated with proteostasis, protein folding/misfolding, ER stress, extracellular clearance)
Senescence (including cells that have halted division, shifted towards a secretory phenotype, altered morphology and epigenetics, and decreased apoptosis)

Other novel targets are encouraged. These include, but are not limited to, the following:

Epigenetics
Vascular pathology
Neuroprotection
Synaptic activity and neurotransmitters
Inflammation
Mitochondrial health
Antioxidant defense
Metabolic function and brain energy
Brain insulin resistance
APOE
Glymphatic clearance
Postnatal neurogenesis
Other aging targets

Letters of Intent (LOI) must be submitted online here and will be accepted through June 3, 2024 at 5:00 pm EDT. We encourage an interactive application process in efforts to solicit the best applications. Scientific inquiries can be directed to either:

Andrew A. Pieper, MD, PhD
Director, Center for Brain Health Medicines
Harrington Discovery Institute
Andrew.Pieper@HarringtonDiscovery.org

or

Meriel Owen, PhD
Director, Search and Evaluation
Alzheimer's Drug Discovery Foundation
mowen@alzdiscovery.org

View original content:https://www.prnewswire.co.uk/news-releases/alzheimers-drug-discovery-foundation-and-harrington-discovery-institute-center-for-brain-health-medicines-invite-proposals-for-2024-addf-harrington-scholar-award-302104548.html

Tags

More Like This

Oxford-Harrington Rare Disease Centre Opens 2025 Call for Proposals

Oxford-Harrington Rare Disease Centre Opens Call for Proposals

The Oxford-Harrington Rare Disease Centre (OHC) Announces Inaugural 2024 Rare Disease Scholar Award Recipients

Dementia Mission Competition Selects Four Companies For Innovative Alzheimer’s Biomarker Study

MULTI-MILLION POUND BOOST FOR RESEARCH PROJECTS AIMED AT DEVELOPING NEW TESTS, TREATMENTS AND DEVICES FOR NEURODEGENERATIVE DISEASES

Alzheimer's Data Challenge Names Winners for Innovative Biomarker Research Competition

The Oxford-Harrington Rare Disease Centre Launches Pioneering Therapeutics Accelerator to Advance Innovative Treatments for Rare Diseases

First-of-its-Kind Bio-Hermes Challenge Sparks Global Interest for Novel Research